Meeting Objectives:
-
-
Identify common breakdowns in bridge program execution, including E1 transaction errors, MBI/Medicare card verification, and misuse of SSN-based inputs, and outline workflow practices used by high-performing pharmacies to avoid them.
-
Examine the patient journey following a bridge denial, including self-pay uptake, abandonment risk, and potential alternative coverage or indication pathways.
-
Discuss real-world considerations in anti-obesity therapy selection and continuity, including formulary re-entry, dose-related efficacy distinctions, and pharmacist-observed patterns in tolerability and treatment persistence.
-
Share This Event